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ABSTRACT
Objectives: To compare the risk of epileptic seizures in adults during conservative management or
following invasive treatment for a brain arteriovenous malformation (AVM).
Methods: We used annual general practitioner follow-up, patient questionnaires, and medical re-
cords surveillance to quantify the 5-year risk of seizures and the chances of achieving 2-year
seizure freedom for adults undergoing AVM treatment compared to adults managed conserva-
tively in a prospective, population-based observational study of adults in Scotland, newly diag-
nosed with an AVM in 1999–2003.
Results: We identified 229 adults with a new diagnosis of an AVM, of whom two-thirds received
AVM treatment (154/229; 67%) during 1,862 person-years of follow-up (median completeness
of follow-up 97%). There was no significant difference in the proportions with a first or recurrent
seizure over 5 years following AVM treatment, compared to the first 5 years following clinical
presentation in conservatively managed adults, in analyses stratified by mode of presentation
(intracerebral hemorrhage, 35% vs 26%, p  0.5; seizure, 67% vs 72%, p  0.6; incidental,
21% vs 10%, p  0.4). For patients with epilepsy, the chances of achieving 2-year seizure
freedom during 5-year follow-up were similar following AVM treatment (n 39; 52%, 95% con-
fidence interval [CI] 36% to 68%) or conservative management (n  21; 57%, 95% CI 35% to
79%; p 0.7).
Conclusions: In this observational study, there was no difference in the 5-year risk of seizures
with AVM treatment or conservative management, irrespective of whether the AVM had pre-
sented with hemorrhage or epileptic seizures. Neurology® 2012;79:500–507
GLOSSARY
AED antiepileptic drug; AVM arteriovenous malformation; CI confidence interval; HR hazard ratio; ICH intracere-
bral hemorrhage; IQR interquartile range; SIVMS Scottish Intracranial Vascular Malformation Study.
Adults with a brain arteriovenous malformation (AVM) are at risk of epileptic seizures, espe-
cially when the AVM is supratentorial (in the temporal lobe in particular) and after intracere-
bral hemorrhage (ICH) has occurred.1 The main aim of AVM treatment is to reduce the risk of
AVM-related ICH, but invasive procedures might also reduce the risk of seizures by obliterat-
ing epileptogenic foci. Conversely, surgical excision, endovascular embolization, and stereotac-
tic radiosurgery could also raise the risk of seizures.
Case series have reported conflicting results about seizure control following AVM treatment:
surgery has been associated with better,2–7 unchanged, or worse seizure control8–10; the effect of
stereotactic radiosurgery has been promising,11–21 although a delayed increase in seizure fre-
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quency has been reported22; the effects of
embolization have been mixed23–27; and the
effects of multimodality AVM treatment have
been promising.28,29 Only 1 observational
study compared the risk of de novo seizures
following AVM surgery to the risk during
conservative management, finding that the
risk was greater following surgery, but the
study was retrospective and based on clinical
practice between 1941 and 1984.30 There
have been no randomized controlled trials to
compare seizure outcomes following AVM
treatment vs conservative management.31
Therefore, we conducted a prospective,
population-based, observational cohort study
and analyzed it to compare the risk of a first
seizure, the risk of epilepsy, and the chances of
achieving 2-year seizure freedom, for adults
undergoing AVM treatment or conservative
management.
METHODS Inclusion criteria. The Scottish Intracranial
Vascular Malformation (IVM) Study (SIVMS) is a prospective,
population-based study that uses anonymized data extracts from
a National Health Service clinical audit of adults aged16 years
resident in Scotland (population 5.1 million) with a new diagno-
sis of an IVM during 1999–2003 and 2006–2010 (The Scottish
Audit of Intracranial Vascular Malformations; www.saivms.scot.
nhs.uk). We identified patients using multiple overlapping
sources of case ascertainment that included a Scotland-wide col-
laborative network of neurologists, neurosurgeons, stroke physi-
cians, radiologists, and pathologists and central registers of
hospital discharges and death certificates.32 We restricted this
analysis to adults with AVMs first diagnosed in 1999–2003 so
that we could accrue at least 5 years of follow-up data for each
patient. We confirmed AVM diagnosis on brain imaging studies
(reviewed by our 2 study neuroradiologists J.J.B. and R.J.S.) or
pathologic examination.
First presentation (inception).We classified a patient’s first
presentation as when they developed symptoms, relevant or not,
that led to an investigation that diagnosed an AVM. We defined
presentation with ICH as a symptomatic event that was associ-
ated with evidence of intracranial blood on brain imaging, CSF,
or postmortem examination. We defined an incidental presenta-
tion as one that could not be related to the underlying AVM.We
classified the initial presentation as epileptic seizure if it was not
symptomatic of a concomitant ICH (seizures symptomatic of
acute ICH were those that were witnessed and occurred within
24 hours of ICH onset). We reviewed all patient records, neuro-
imaging, and pathology reports and attributed seizures to the
AVM if there was no better explanation for them. We reviewed
patient records to identify prior episodes of symptomatic ICH
and seizures. We calculated hematoma volume using axial brain
imaging and the ABC/2 method and measured maximum AVM
nidus diameter on MRI or catheter angiography (pial arterio-
venous fistulae without a nidus were scored as 0 cm).
Follow-up. Prospective follow-up started from the date of first
presentation (defined as the date on which the patient developed
symptoms that led to the diagnosis of an AVM) for conserva-
tively managed patients and from the date of first intervention
for the treated group. We used annual surveillance of general
(family) practitioner and hospital medical records, as well as an-
nual questionnaires to general practitioners and consenting pa-
tients, to establish patients’ medical histories, mode of clinical
presentation, events during follow-up, and antiepileptic drug
Table 1 Clinical characteristics of patients undergoing conservative
management or invasive treatment following intracranial
hemorrhage due to an arteriovenousmalformation (AVM)a
Conservative
(n 24)
AVM treatment
(n 91)
Age at presentation, y 57 (41–74) 46 (34–54)
Female 14 (58) 40 (44)
History of seizures prior to presentation 2 (8) 13 (14)
Symptomatic seizure at presentation with ICH 1 (4) 14 (15)
Already on AED prior to first seizure 3 (13) 8 (9)
Intracranial hemorrhage
Intraparenchymal hemorrhage 19 (79) 71 (78)
Volume, cm3 8 (4–34) 17 (5–43)
Lobar 13 (68) 53 (75)
Deep 4 (21) 6 (8)
Infratentorial 2 (11) 12 (17)
Pure SAH 0 (0) 6 (7)
Pure IVH 1 (4) 10 (11)
IVH and SAH 4 (17) 3 (3)
SDH 0 (0) 1 (1)
AVM location
Right hemisphere 11 (46) 56 (62)
Left hemisphere 11 (46) 31 (34)
Midline 2 (8) 4 (4)
Lobar 15 (63) 67 (74)
Deep 5 (20) 9 (10)
Infratentorial 4 (17) 15 (16)
AVM nidusmaximum diameter, cm 2.2 (1.4–3.0) 2.0 (1.2–3.0)
Spetzler-Martin grade 2.5 (2–3) 2 (1–3)
Intervention
Surgery N/A 28 (31)
Surgery embolization N/A 13 (14)
Surgery embolization radiosurgery N/A 1 (1)
Embolization N/A 16 (18)
Embolization radiosurgery N/A 16 (18)
Radiosurgery N/A 17 (18)
AVM obliterated on latest imaging
Yes 2 (8) 61 (67)
No 6 (25) 23 (25)
Unknown (no angiogram performed) 16 (67) 7 (8)
Abbreviations: AED  antiepileptic drug; deep  basal ganglia, choroid plexus, hypothala-
mus, thalamus, and limbic structures; IQR interquartile range; IVH intraventricular hem-
orrhage; SAH subarachnoid hemorrhage; SDH subdural hematoma.
a Values are n (%) or median (IQR).
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(AED) prescriptions. We evaluated completeness of follow-up
by comparing all follow-up successfully obtained to the maxi-
mum amount of follow-up that was potentially available using
these multiple sources.33 If an adult had no history of epileptic
seizures prior to presentation, then their first-ever seizure was the
initial one that occurred at presentation (unprovoked by ICH)
or during prospective follow-up, and we determined their devel-
opment of epilepsy as when they had their next seizure during
prospective follow-up. If the exact day or month of a seizure was
not available, we imputed the date as the midpoint of the month
or year, respectively.
Statistical analysis. We used parametric statistics to compare
demographic, clinical, and radiologic characteristics between the
groups when the data were normally distributed and nonpara-
metric statistics when they were not. We performed survival
analysis using life tables and Kaplan-Meier statistics. We cen-
sored patients on the date of death, last available follow-up, or at
the end of 5-year follow-up if an event of interest did not occur.
We evaluated time to first seizure during prospective follow-up
during conservative management (follow-up started at clinical
presentation) vs after AVM treatment (follow-up started at the
time of first intervention) according to their mode of presenta-
tion (ICH, seizure, or incidental). We subdivided patients ac-
cording to the type of intervention received when analyzing time
to next seizure in adults presenting with a seizure (because there
were sufficient numbers of patients and outcome events to en-
able us to do this). We hypothesized that early seizure risk after
AVM treatment would be greatest in patients who underwent
surgery (due to the craniotomy and the potential impact on the
surrounding brain tissue), followed by embolization, and then
stereotactic radiosurgery. Therefore, if a patient underwent mul-
timodality AVM treatment, we classified them in the surgery
category if they ever underwent surgical excision, in the emboli-
zation category if they never underwent surgery (irrespective of
whether they received stereotactic radiosurgery), and in the ste-
reotactic radiosurgery category if they underwent this procedure
but never had surgery or embolization. We evaluated time to
2-year seizure freedom in patients who presented with seizures
and epilepsy (there were too few outcome events to permit these
analyses for adults with other modes of initial presentation). We
performed univariable comparisons using the log-rank test and
multivariable Cox regression analyses only when the propor-
tional hazards assumption was met,34 and prespecified the inclu-
sion of AVM treatment, hematoma volume, and the occurrence
of symptomatic seizures at the time of ICH1 in a multivariable
analysis of factors that may increase the risk of seizures for adults
who presented with ICH. We used a sensitivity analysis to eval-
uate our decision to include adults with both a single seizure and
established epilepsy before AVM diagnosis in the time to 2-year
seizure freedom analysis. All statistical tests were 2-tailed ( 
0.05) and performed using SPSS (version 14.0).
Standard protocol approvals, registrations, and patient
consents. We performed analyses on anonymized extracts of
The Scottish Audit of Intracranial Vascular Malformations data-
set. The Multicenter Research Ethics Committee for Scotland
(MREC/98/0/48) and the Fife and Forth Valley Research Ethics
Committee (08/S0501/76) approved SIVMS and the conduct of
postal questionnaires.
RESULTS We identified 229 adults first diagnosed
in 1999–2003 with a definite AVM for whom there
was a total of 1,862 person-years of follow-up (me-
dian 9 years per person, interquartile range [IQR] 7
to 10 years) with a median completeness of follow-up
of 97% (IQR 96% to 100%) on February 18,
2011.35 Half of these adults (n  115) presented
with intracranial hemorrhage, 60 (26%) presented
with epileptic seizures, 44 (19%) AVMs were inci-
dental discoveries, and the remaining 10 (5%) (not
analyzed further in this article) presented with a focal
neurologic deficit in the absence of intracranial hem-
orrhage. Two-thirds of the adults included in our
analyses (149/219; 68%) had AVM treatment.
Effect of AVM treatment on risk of seizures for adults
presenting with ICH. Most patients with ICH (91/
115; 79%) underwent AVM treatment. All patients
undergoing hematoma evacuation underwent con-
current AVM resection or embolization. Adults in
the treated group were younger (p 0.001) but oth-
erwise demographic characteristics did not signifi-
cantly differ between groups (table 1). AVM
treatment obliterated two-thirds of AVMs (table 1).
During 560 person-years of follow-up (median
5.6 years per person, IQR 0.4 to 8 years), the 5-year
risk of a first unprovoked seizure was not signifi-
cantly different during conservative management
(n  24; 26% [95% CI 2% to 50%]) or following
first AVM treatment (n 91; 35% [95% CI 25% to
45%], p  0.5; figure 1). All adults with a temporal
lobe AVM (n 8) who presented with ICH received
Figure 1 The 5-year risk of a first-ever unprovoked seizure after
intracranial hemorrhage
The 5-year risk of a first-ever unprovoked seizure after presentation for adults with an
arteriovenous malformation (AVM) who presented with intracranial hemorrhage and were
managed conservatively (black line; follow-up started at initial clinical presentation) or with
AVM treatment (red line; follow-up started at first invasive procedure). CI  confidence
interval.
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AVM treatment. Temporal lobe AVMs have been
associated with an increased risk of seizures in this
cohort,1 but in a sensitivity analysis in which we re-
moved the 8 adults with a temporal lobe AVM from
the analysis there remained no significant difference
in the 5-year risk of a first-ever unprovoked seizure
between adults receiving conservative management
or AVM treatment (p  0.6). The 5-year risk of a
first unprovoked seizure was not greater in those
whose treatment resulted in incomplete AVM oblit-
eration (p  0.14).
Because age at presentation was the only definite
baseline difference between the 2 groups (table 1),
and because there were 36 outcomes, we included
this variable with our 3 prespecified variables in a
Cox proportional hazards analysis of predictors of
seizures for adults presenting with ICH. Only he-
matoma volume on the first CT scan following
presentation with symptomatic ICH significantly
influenced the 5-year risk of a first seizure during
follow-up (hazard ratio [HR]  1.02 [95% CI 1.01
to 1.04]; p  0.001); the occurrence of a symptom-
atic seizure at ICH onset (HR 2.4 [95% CI 0.9 to
6.2]; p  0.07), receipt of AVM treatment (HR 
3.0 [95% CI 0.4 to 24]; p 0.3), and age at presen-
tation (HR  1.0 [95% CI 0.98 to 1.03]; p  0.8)
did not independently influence this risk.
Effect of AVM treatment on risk of recurrent seizures
in adults presenting with a seizure. Most adults who
presented with an unprovoked seizure underwent
AVM treatment, and these adults were younger (p
0.005), a larger proportion was already on an AED at
the start of prospective follow-up (p  0.001), and
they more frequently had left hemispheric AVMs
(p  0.03; table 2). The proportion of adults with a
temporal lobe AVM was similar in the conservatively
managed group (7/21 [33%]) and after AVM treat-
ment (13/39 [33%]; p 0.6). AVM treatment oblit-
erated almost three-quarters of AVMs (table 2).
During 170 person-years of follow-up (median
0.7 years per person, IQR 0.2 to 6 years, in view of
the large number of outcomes in the first year), the
5-year risk of a recurrent unprovoked seizure during
conservative management (72% [95% CI 52% to
92%]) was not significantly different from that fol-
lowing first AVM treatment (67% [95% CI 51% to
83%], p  0.6; figure e-1 on the Neurology® Web
site at www.neurology.org). The 5-year risk of a re-
current unprovoked seizure did not differ according
to the type of AVM treatment (figure e-2) or accord-
ing to whether the AVM was obliterated following
treatment (p  0.6).
Effect of AVM treatment on the chance of 2-year sei-
zure freedom in adults presenting with a seizure. Of
the 60 adults who first presented with seizures due to
their AVM, by 2 years 76% (16/21) of the conserva-
tively managed group and 77% (30/39) of the AVM
treatment group developed epilepsy. The chance of
achieving 2-year seizure freedom over 5 years of pro-
spective follow-up did not differ between the 21 con-
servatively managed adults (57% [95% CI 35% to
79%]) and the 39 adults undergoing AVM treatment
(52% [95% CI 36% to 68%], p  0.7; figure 2).
Similar proportions of adults in both the conserva-
tively managed and AVM treatment groups were on
Table 2 Clinical characteristics of patients undergoing conservative
management or invasive treatment following presentation with a
seizure related to an arteriovenousmalformation (AVM)a
Conservative
(n 21)
AVM treatment
(n 39)
Age at presentation, y 49 (36–57) 37 (34–54)
Female 6 (29) 15 (38)
History of ICH prior to start of follow-up 1 (5) 2 (5)
No. with epilepsy at the start of prospective
follow-up
7 (33) 18 (46)
No. already on an AED at the start of
prospective follow-up
2 (10) 32 (82)
AVM location
Right hemisphere 12 (57) 9 (23)
Left hemisphere 9 (43) 29 (74)
Midline 0 (0) 1 (3)
Lobar 21 (100) 36 (92)
Deep 0 (0) 3 (8)
Infratentorial 0 (0) 0 (0)
AVM nidusmaximum diameter, cm 3.0 (1.8–4.0) 3.0 (2.0–4.0)
Spetzler-Martin grade 2 (2–3) 2 (2–3)
Intervention
Surgery N/A 4 (10)
Surgery embolization N/A 9 (23)
Surgery embolization radiosurgery N/A 0 (0)
Embolization N/A 11 (28)
Embolization radiosurgery N/A 8 (21)
Radiosurgery N/A 7 (18)
AVM obliterated on latest imaging
Yes 1 (5) 28 (72)
No 1 (5) 10 (25)
Unknown (no angiogram performed) 19 (90) 1 (3)
AED use at the end of follow-up
Monotherapy 12 (57) 22 (56)
Polytherapy 4 (19) 7 (18)
AEDwithdrawn 4 (19) 7 (18)
Never prescribed an AED 1 (5) 3 (8)
Abbreviations: AED  antiepileptic drug; deep  basal ganglia, choroid plexus, hypothala-
mus, thalamus, and limbic structures; ICH  intracerebral hemorrhage; IQR  interquartile
range.
a Values are n (%) or median (IQR).
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AED therapy at the end of follow-up (p 0.3; table
2). The chance of achieving 2-year seizure freedom
remained similar between groups in a sensitivity
analysis involving only those with established epi-
lepsy at the time of initial presentation (47% [95%
CI 23% to 71%] during conservative management vs
61% [95% CI 39% to 83%] following first AVM
treatment, p  0.3).
Effect of AVM treatment on risk of first-ever seizure
for adults with an incidentally discovered AVM.
Among adults with an AVM diagnosed despite hav-
ing no symptoms or unrelated symptoms, those who
were conservatively managed were older than those
undergoing AVM treatment (p  0.002), but base-
line characteristics did not differ otherwise (table 3).
AVM treatment obliterated nearly four-fifths of
AVMs. During 250 person-years of follow-up (me-
dian 7 years per person, IQR 1 to 8 years), the 5-year
risk of a first unprovoked seizure was not signifi-
cantly different between conservatively managed
adults and those undergoing AVM treatment (figure
e-3). The 5-year risk of a first unprovoked seizure
was not greater in those whose treatment resulted in
incomplete AVM obliteration (p  0.5).
DISCUSSION In this prospective, population-based
observational study, the risk of first-ever or recurrent
seizures following AVM treatment did not differ
from that seen in conservatively managed adults, ir-
respective of their mode of presentation. The only
variable associated with a greater prospective risk of
seizures was increasing hematoma volume in adults
who had presented with ICH.
AVM treatment did not influence either the
5-year risk of a recurrent seizure or the chance of
achieving 2-year seizure freedom in patients who had
presented with an unprovoked seizure. Significantly
more of the adults in the treatment group were
already being treated with an AED at the start of
follow-up, but by the end of follow-up similar pro-
portions were on AEDs (table 2). The risk of a
first-ever seizure following AVM treatment for un-
ruptured incidental AVMs appeared higher than
with conservative management although this differ-
ence was not statistically significant (figure e-3),
which is consistent with our previous finding that
AVM treatment independently worsens short-term
outcome for adults with unruptured AVMs.36
Our study has benefited from multiple overlap-
ping sources of case ascertainment and a median
completeness of follow-up of 97%. The crude detec-
tion rate of AVMs in the first 2 years of our study in
Scotland was not significantly different from the
pooled detection rate in a recent meta-analysis.37,38
The population-based design of our study sought to
avoid referral and selection biases. Largely because of
the logistical and financial constraints involved with
studying a geographically dispersed population, we
relied on clinicians’ evaluations in patients’ medical
records as well as questionnaire data to patients
and their family practitioners, rather than regu-
larly scheduled study visits. The use of 2-year sei-
zure freedom (rather than 1-year seizure freedom)
should limit reporting bias that may exist in pa-
tients with a long-standing history of epilepsy who
may be less inclined to present to medical atten-
tion as a result of a seizure, and this outcome mea-
sure is directly relevant to clinical practice since
AEDs tend not to be withdrawn until a patient is
at least 2 years seizure-free.39
Due to the complexities of AVM treatment, we
simplified the analysis by starting follow-up from the
time of first-ever intervention, and allocating a single
mode of intervention to those undergoing multimo-
dality treatment (and consequently the time to first
seizure in the surgery group may have been overesti-
mated among patients who received presurgical emboli-
zation). AVM treatment obliterated approximately
three-quarters of the AVMs, which is similar to the
findings of everyday practice at other institutions.
The 5-year risk of a seizure did not differ according
to whether treatment resulted in complete or incom-
plete AVM obliteration. We could not perform a
Figure 2 Chance of achieving 2-year seizure freedom for adults over
5 years follow-up
The 5-year chance of achieving 2-year seizure freedom in adults with an arteriovenous
malformation (AVM) who presented with a seizure and were managed conservatively (black
line; follow-up started at initial clinical presentation) or with AVM treatment (red line;
follow-up started at first invasive procedure). CI confidence interval.
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multivariable analysis of factors that contribute to
the 5-year risk of a recurrent seizure or the chances of
achieving 2-year seizure freedom in adults presenting
with unprovoked seizures due to the fact that the
survival curves did not satisfy the assumptions of the
Cox proportional hazards model. However, receipt
of AVM treatment did not appear to affect the risk of
recurrent seizure or chance of 2-year seizure freedom
in adults with AVM-related epilepsy. The effect of
AVM treatment may have been modified by the
greater proportion of adults on an AED at the start
of follow-up (because immediate AED use does in
general delay time to first and second seizure, and
appears to reduce time to 2-year seizure freedom40)
and such an imbalance would have been expected
to favor the AVM treatment group. However,
equivalent proportions of adults were on AED by
the end of follow-up (table 2). Finally, the lack of
statistically significant differences may be due to a
type II error on account of sample size, and we
have recruited a second 5-year cohort to address
this in future analyses.
While AVM treatment may reduce the risk of re-
bleeding, our observational study could not demon-
strate a difference between AVM treatment and
conservative management on the clinical course of
epileptic seizures. We cannot, however, rule out the
influence of confounding in a nonrandomized study.
Although the differences were not statistically signif-
icant, adults undergoing AVM treatment had higher
frequencies of seizures prior to presentation, symp-
tomatic seizures at ICH onset, temporal lobe AVM
location, and these adults may have had a higher pro-
spective risk of seizures. Further recruitment and
follow-up will improve the precision of our estimates
of seizure risk and allow us to expand our multivari-
able analyses of factors that might influence the de-
velopment of de novo seizures and predict seizure
control. Randomized controlled trials, such as A
Randomized trial of Unruptured Brain Arterio-
venous Malformations (ARUBA, www.arubastudy.
org, ISRCTN 44013133), are required to confirm or
refute our findings.
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Table 3 Clinical characteristics of patients undergoing conservative
management or invasive treatment following presentation with
symptoms incidental to their arteriovenousmalformation (AVM)a
Conservative
(n 25)
AVM treatment
(n 19)
Age at presentation, y 59 (48–75) 46 (35–55)
Female 13 (52) 8 (42)
No. with a history of seizures prior to
presentation
3 (12) 1 (5)
No. already on an AED at start of
prospective follow-up
4 (16) 3 (16)
AVM location
Right hemisphere 13 (52) 8 (42)
Left hemisphere 11 (44) 9 (47)
Midline 1 (4) 2 (11)
Lobar 21 (84) 16 (84)
Deep 1 (4) 3 (16)
Infratentorial 3 (12) 0 (0)
AVM nidusmaximum diameter, cm 3.5 (2.8–4.6) 2.0 (1.8–4.3)
Spetzler-Martin grade 3 (2–4) 2 (1–3)
Intervention
Surgery N/A 1 (5)
Surgery embolization N/A 4 (21)
Surgery embolization radiosurgery N/A 0 (0)
Embolization N/A 6 (32)
Embolization radiosurgery N/A 3 (16)
Radiosurgery N/A 5 (26)
AVM obliterated on latest imaging
Yes 0 (0) 15 (79)
No 0 (0) 4 (21)
Unknown (no angiogram performed) 25 (100) 0 (0)
Abbreviations: AED  antiepileptic drug; deep  basal ganglia, choroid plexus, hypothala-
mus, thalamus, and limbic structures; ICH  intracerebral hemorrhage; IQR  interquartile
range.
a Values are n (%) or median (IQR).
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